Nimble Rx Startup Diligence Report
Track as a prescription-commerce and pharmacy enablement platform; require HIPAA/privacy evidence, pharmacy and manufacturer contracts, cohort retention, take-rate economics, claim substantiation and cap-table detail before underwriting.
Nimble Rx Startup Diligence Report
Nimble Rx is an active private healthcare technology unicorn candidate with a current product site, public pharmacy/manufacturer/patient workflows, and CB Insights valuation support. Public evidence is strongest for product positioning and pharmacy network claims; it is weakest for financial quality, revenue concentration, compliance detail and valuation durability.
Opaque valuation, revenue quality and unit economics is material because valuation, revenue quality, concentration and current financing terms require private records.
Diligence request: Request audited financials, cap table, current mark, revenue bridge, backlog, retention and sensitivity analysis.
Competition and channel dependency across independent pharmacies, chains, PBMs and large retailers requires counsel-led review because public evidence is incomplete for contracts, licenses, disputes, privacy/security and regulatory obligations.
Diligence request: Request legal schedule, regulatory filings, litigation docket, insurance, employment agreements, policies and compliance attestations.
Several public sources are company-owned, stale, statistical, or secondary-market profiles; material conclusions must be confirmed directly.
Diligence request: Do not rely on this public report as a substitute for data-room diligence and management interviews.
Healthcare privacy, pharmacy compliance and payments risk could impair growth if public product and GTM claims do not translate into repeatable delivery economics.
Diligence request: Request implementation metrics, roadmap, budget, product reliability, supplier contracts and customer references.
Public evidence confirms Nimble Rx's unicorn-list valuation and selected financing/profile anchors, but financial statements, customer economics and capitalization are private. Section I (Financial Information) is therefore classified using public evidence plus explicit gaps.
partially verified confidence: medium
Public evidence confirms Nimble Rx's unicorn-list valuation and selected financing/profile anchors, but financial statements, customer economics and capitalization are private. Section I.A (Annual and quarterly financial information for the past three years) is therefore classified using public evidence plus explicit gaps.
| Record | Public evidence | Diligence status | Request |
|---|---|---|---|
| Audited financial statements | No audited statements found in public sources | not_publicly_verifiable | Three years of income statement, balance sheet, cash flow and footnotes |
| Revenue by customer / product | IncFact provides only broad statistical revenue range | not_publicly_verifiable | Revenue, gross margin, ARR/backlog and customer concentration schedules |
| Cash runway and debt | No bank lines, notes, payables or burn rate disclosed | not_publicly_verifiable | Cash balance, burn, debt instruments, warrants, liens and off-balance-sheet commitments |
not publicly verifiable confidence: high
Public evidence confirms Nimble Rx's unicorn-list valuation and selected financing/profile anchors, but financial statements, customer economics and capitalization are private. Section I.B (Financial Projections) is therefore classified using public evidence plus explicit gaps.
partially verified confidence: medium
Public evidence confirms Nimble Rx's unicorn-list valuation and selected financing/profile anchors, but financial statements, customer economics and capitalization are private. Section I.C (Capital Structure) is therefore classified using public evidence plus explicit gaps.
partially verified confidence: medium
Public evidence confirms Nimble Rx's unicorn-list valuation and selected financing/profile anchors, but financial statements, customer economics and capitalization are private. Section I.D (Other financial information) is therefore classified using public evidence plus explicit gaps.
| Date | Event | Amount or valuation | Investors / counterparties | Verification |
|---|---|---|---|---|
| 2022-06-14 | Unicorn-list valuation | $1.40B | Sequoia Capital, Four Rivers Group, DAG Ventures | CB Insights public tracker |
| Most recent public financing / profile signal | Private-market and statistical profile signals | Revenue estimate $10M-$100M; valuation $1.40B per CB Insights | Sequoia Capital, Four Rivers Group, DAG Ventures | Public source; data-room confirmation needed |
| Current | Cap table and current mark | not_publicly_verifiable | Company / investors | Request fully diluted cap table and latest financing documents |
Amounts are public anchors, not audited company financials.
Public company sources describe the product portfolio and core workflows; pricing, margins and implementation performance need company data. Section II (Products) is therefore classified using public evidence plus explicit gaps.
partially verified confidence: medium
Public company sources describe the product portfolio and core workflows; pricing, margins and implementation performance need company data. Section II.A (Description of each product) is therefore classified using public evidence plus explicit gaps.
| Product | Audience | Publicly described features | Verification |
|---|---|---|---|
| Nimble for Pharmacies | Independent retail pharmacies | Digital ordering, checkout, refills, payments, pickup, marketing and revenue optimization | verified |
| Nimble for Patients | Prescription patients | App to manage prescription information, reminders, payment, delivery and pickup | verified |
| Nimble for Manufacturers | Life-science companies | Adherence, abandonment and awareness programs using pharmacy/patient workflows | verified |
| Experience Payments | Pharmacies | Program compensating pharmacies when patients complete the Nimble experience | partially_verified |
| Offer | Pricing / package signal | Evidence | Verification |
|---|---|---|---|
| Pharmacy platform | Contract / SaaS or transaction economics not public | Nimble describes revenue and checkout benefits but not fees | not_publicly_verifiable |
| Experience Payments | Performance or participation economics | Public page says pharmacies are compensated for completed Nimble experience | partially_verified |
| Manufacturer programs | Custom-built adherence / abandonment / awareness programs | No public rate card or take-rate disclosed | not_publicly_verifiable |
| Patient app | Consumer-facing app | App store links public; patient pricing and delivery fees not fully public in collected sources | partially_verified |
Public sources identify customer, partner or traction signals, but revenue contribution, concentration and renewal terms are not public. Section III (Customer Information) is therefore classified using public evidence plus explicit gaps.
partially verified confidence: medium
Public sources identify customer, partner or traction signals, but revenue contribution, concentration and renewal terms are not public. Section III.A (Top customers by application) is therefore classified using public evidence plus explicit gaps.
| Customer / partner | Type | Public evidence | Verification |
|---|---|---|---|
| Hundreds of independent retail pharmacies | Pharmacy customers / partners | Company pharmacy page claims hundreds rely on Nimble | partially_verified |
| Patients of independent, chain and specialty pharmacies | End users | Manufacturer page claims millions of patients can manage/order/pay online | partially_verified |
| Life-science manufacturers | B2B marketing / adherence buyers | Manufacturer page says leading life-science companies partner with Nimble | partially_verified |
| AAP-affiliated pharmacy channel | Association / partner signal | Pharmacy page says Nimble is a preferred partner of AAP | partially_verified |
not publicly verifiable confidence: high
Public sources identify customer, partner or traction signals, but revenue contribution, concentration and renewal terms are not public. Section III.B (Strategic relationships) is therefore classified using public evidence plus explicit gaps.
partially verified confidence: medium
Public sources identify customer, partner or traction signals, but revenue contribution, concentration and renewal terms are not public. Section III.C (Revenue by customer) is therefore classified using public evidence plus explicit gaps.
not publicly verifiable confidence: high
Public sources identify customer, partner or traction signals, but revenue contribution, concentration and renewal terms are not public. Section III.D (Significant relationships severed within the last two years) is therefore classified using public evidence plus explicit gaps.
partially verified confidence: medium
Public sources identify customer, partner or traction signals, but revenue contribution, concentration and renewal terms are not public. Section III.E (Top suppliers) is therefore classified using public evidence plus explicit gaps.
| Dependency | Role | Risk note | Verification |
|---|---|---|---|
| Pharmacy management system integrations | Order, refill and workflow integration | Company lists integration with major systems | verified |
| AWS secure infrastructure | Hosting / security claim | Pharmacy page says AWS Secure | partially_verified |
| Payment and processing providers | Encrypted payments and processing | Company page lists encrypted payment and processing | partially_verified |
| LegitScript / healthcare compliance posture | Trust and compliance signal | Company footer includes LegitScript approval seal | partially_verified |
The competitive set can be mapped from public market context, yet market share, win/loss and pricing pressure are not public. Section IV (Competition) is therefore classified using public evidence plus explicit gaps.
partially verified confidence: medium
The competitive set can be mapped from public market context, yet market share, win/loss and pricing pressure are not public. Section IV.A (Competitive landscape by market segment) is therefore classified using public evidence plus explicit gaps.
| Competitor | Segment | Overlap | Primary competitive axis |
|---|---|---|---|
| CVS / CVS Pharmacy | Large integrated pharmacy retailer | Competes for prescription fulfillment and patient app mindshare | Scale and payer relationships |
| Walgreens | National pharmacy chain | Competes for prescription convenience and delivery | Retail footprint and brand |
| Amazon Pharmacy / PillPack | Online pharmacy and logistics | Competes on digital ordering and delivery experience | Logistics and consumer ecosystem |
| GoodRx / Blink Health / Phil | Prescription commerce and access platforms | Compete around patient acquisition, savings, adherence and fulfillment workflows | Distribution and manufacturer programs |
| Axis | Target public position | Competitor pressure | Diligence need |
|---|---|---|---|
| Product differentiation | Public sources support a differentiated product story | High | Technical validation, win/loss and customer references |
| Distribution / channel access | Some public partner/channel evidence | High | Pipeline conversion, renewal and CAC evidence |
| Cost / unit economics | not_publicly_verifiable | High | Gross margin, contribution margin and pricing schedules |
Owned pages and news/profile sources show GTM motions; CAC, pipeline, quota productivity and conversion are private. Section V (Marketing, Sales, and Distribution) is therefore classified using public evidence plus explicit gaps.
partially verified confidence: medium
Owned pages and news/profile sources show GTM motions; CAC, pipeline, quota productivity and conversion are private. Section V.A (Strategy and implementation) is therefore classified using public evidence plus explicit gaps.
| Signal | Description | Evidence strength |
|---|---|---|
| Solution pages | Owned content maps pharmacy, patient and manufacturer use cases | verified |
| LegitScript seal and compliance messaging | Trust-building for pharmacy/patient flows | partially_verified |
| Third-party financial/profile pages | Forge and IncFact provide external signals but also disclaim limitations | partially_verified |
not publicly verifiable confidence: high
Owned pages and news/profile sources show GTM motions; CAC, pipeline, quota productivity and conversion are private. Section V.B (Major Customers) is therefore classified using public evidence plus explicit gaps.
partially verified confidence: medium
Owned pages and news/profile sources show GTM motions; CAC, pipeline, quota productivity and conversion are private. Section V.C (Principal avenues for generating new business) is therefore classified using public evidence plus explicit gaps.
| Channel | Motion | Public evidence | Verification |
|---|---|---|---|
| Pharmacy direct sales | Demo-driven sales to independent pharmacies | Company has pharmacy demo calls and operations claims | verified |
| Manufacturer partnerships | B2B programs for adherence, abandonment and awareness | Manufacturer page describes custom-built life-science solutions | verified |
| Patient app distribution | App Store / Google Play patient acquisition | Homepage links mobile apps and patient login | verified |
| Association / network channel | AAP preferred partner signal | Pharmacy page says preferred partner of AAP | partially_verified |
not publicly verifiable confidence: high
Owned pages and news/profile sources show GTM motions; CAC, pipeline, quota productivity and conversion are private. Section V.D (Sales force productivity model) is therefore classified using public evidence plus explicit gaps.
not publicly verifiable confidence: high
Owned pages and news/profile sources show GTM motions; CAC, pipeline, quota productivity and conversion are private. Section V.E (Ability to implement marketing plan with current and projected budgets) is therefore classified using public evidence plus explicit gaps.
Roadmap and R&D claims are visible only at a high level; budgets, technical debt, staffing and validation artifacts require direct diligence. Section VI (Research and Development) is therefore classified using public evidence plus explicit gaps.
partially verified confidence: medium
Roadmap and R&D claims are visible only at a high level; budgets, technical debt, staffing and validation artifacts require direct diligence. Section VI.A (Description of R&D organization) is therefore classified using public evidence plus explicit gaps.
| Person / role | Function | Public evidence | Verification |
|---|---|---|---|
| Talha Sattar | CEO / founder | Forge page lists Talha Sattar as CEO and founder in company details | partially_verified |
| Ryan Brown | CFO | Forge page lists Ryan Brown as CFO | partially_verified |
| Product / integration teams | Pharmacy management integrations and patient messaging | Company pages describe integrations and optimized messages | partially_verified |
partially verified confidence: medium
Roadmap and R&D claims are visible only at a high level; budgets, technical debt, staffing and validation artifacts require direct diligence. Section VI.B (New Product Pipeline) is therefore classified using public evidence plus explicit gaps.
| Initiative | Status | Evidence | Verification |
|---|---|---|---|
| Digital ordering and operations | Active | Core pharmacy product live on company site | verified |
| Manufacturer adherence / abandonment / awareness programs | Active | Manufacturer page describes three program categories | verified |
| Experience Payments | Active / marketed | Pharmacy page describes compensation for completed Nimble experience | partially_verified |
| Data and targeting capabilities | Active / sensitive | Manufacturer page cites recent and relevant data plus real-time actionable data | partially_verified |
Public leadership and headcount signals are incomplete; org chart, compensation, retention and turnover records are private. Section VII (Management and Personnel) is therefore classified using public evidence plus explicit gaps.
partially verified confidence: medium
Public leadership and headcount signals are incomplete; org chart, compensation, retention and turnover records are private. Section VII.A (Organization Chart) is therefore classified using public evidence plus explicit gaps.
partially verified confidence: medium
Public leadership and headcount signals are incomplete; org chart, compensation, retention and turnover records are private. Section VII.B (Historical and projected headcount by function and location) is therefore classified using public evidence plus explicit gaps.
| Function / metric | Public signal | Evidence | Verification |
|---|---|---|---|
| Company-size estimate | 10-100 employees | IncFact estimates 10-100 employees | partially_verified |
| Revenue estimate | $10M-$100M annual revenue | IncFact estimates revenue range and cautions it is statistical | partially_verified |
| Exact function/location plan | Private | No public historical headcount schedule found | not_publicly_verifiable |
partially verified confidence: medium
Public leadership and headcount signals are incomplete; org chart, compensation, retention and turnover records are private. Section VII.C (Senior management biographies) is therefore classified using public evidence plus explicit gaps.
| Name / role | Title | Public evidence | Verification |
|---|---|---|---|
| Talha Sattar | Chief Executive Officer | Forge company details list Talha Sattar as CEO | partially_verified |
| Ryan Brown | Chief Financial Officer | Forge company details list Ryan Brown as CFO | partially_verified |
| Functional leaders | Product, pharmacy partnerships, compliance, engineering | Not publicly mapped in collected sources | not_publicly_verifiable |
not publicly verifiable confidence: high
Public leadership and headcount signals are incomplete; org chart, compensation, retention and turnover records are private. Section VII.D (Compensation arrangements) is therefore classified using public evidence plus explicit gaps.
not publicly verifiable confidence: high
Public leadership and headcount signals are incomplete; org chart, compensation, retention and turnover records are private. Section VII.E (Incentive stock plans) is therefore classified using public evidence plus explicit gaps.
not publicly verifiable confidence: high
Public leadership and headcount signals are incomplete; org chart, compensation, retention and turnover records are private. Section VII.F (Significant employee relations problems, past or present) is therefore classified using public evidence plus explicit gaps.
not publicly verifiable confidence: high
Public leadership and headcount signals are incomplete; org chart, compensation, retention and turnover records are private. Section VII.G (Personnel Turnover) is therefore classified using public evidence plus explicit gaps.
Legal and regulatory diligence must rely on public signals plus counsel schedules because contracts, licenses, insurance and dockets are incomplete publicly. Section VIII (Legal and Related Matters) is therefore classified using public evidence plus explicit gaps.
partially verified confidence: medium
Legal and regulatory diligence must rely on public signals plus counsel schedules because contracts, licenses, insurance and dockets are incomplete publicly. Section VIII.A (Pending lawsuits against the Company) is therefore classified using public evidence plus explicit gaps.
| Matter | Category | Public evidence | Verification |
|---|---|---|---|
| HIPAA / healthcare privacy | Patient prescription and health data exposure | Privacy policy collected; detailed HIPAA controls not public | partially_verified |
| Payments compliance | Encrypted payment and processing public claim | Provider contracts and PCI evidence private | partially_verified |
| LegitScript approval | Pharmacy trust/compliance signal | Homepage footer includes LegitScript approval seal link | partially_verified |
| Pending litigation / regulatory actions | No complete docket or regulator search in public evidence | not_publicly_verifiable | — |
not publicly verifiable confidence: high
Legal and regulatory diligence must rely on public signals plus counsel schedules because contracts, licenses, insurance and dockets are incomplete publicly. Section VIII.B (Pending lawsuits initiated by Company) is therefore classified using public evidence plus explicit gaps.
not publicly verifiable confidence: high
Legal and regulatory diligence must rely on public signals plus counsel schedules because contracts, licenses, insurance and dockets are incomplete publicly. Section VIII.C (Environmental and employee safety issues and liabilities) is therefore classified using public evidence plus explicit gaps.
partially verified confidence: medium
Legal and regulatory diligence must rely on public signals plus counsel schedules because contracts, licenses, insurance and dockets are incomplete publicly. Section VIII.D (Material patents, copyrights, licenses, and trademarks) is therefore classified using public evidence plus explicit gaps.
| Asset / contract | Type | Public evidence | Verification |
|---|---|---|---|
| NimbleRx platform and data workflows | Software and trade secrets | Company pages describe workflows; patent schedule not public | partially_verified |
| Pharmacy system integrations | Third-party integration contracts | Integration logos visible; contracts and exclusivity private | partially_verified |
| Manufacturer program contracts | Marketing/adherence contracts | Life-science partner names and economics not public | not_publicly_verifiable |
not publicly verifiable confidence: high
Legal and regulatory diligence must rely on public signals plus counsel schedules because contracts, licenses, insurance and dockets are incomplete publicly. Section VIII.E (Insurance coverage and material exposures) is therefore classified using public evidence plus explicit gaps.
not publicly verifiable confidence: high
Legal and regulatory diligence must rely on public signals plus counsel schedules because contracts, licenses, insurance and dockets are incomplete publicly. Section VIII.F (Material contracts) is therefore classified using public evidence plus explicit gaps.
partially verified confidence: medium
Legal and regulatory diligence must rely on public signals plus counsel schedules because contracts, licenses, insurance and dockets are incomplete publicly. Section VIII.G (Regulatory agency problems) is therefore classified using public evidence plus explicit gaps.
| ID | Claim | Status | Sources |
|---|---|---|---|
| EC-001 | CB Insights lists Nimble Rx as a United States / Redwood City Healthcare & Life Sciences unicorn with $1.40B valuation and investors Sequoia Capital, Four Rivers Group and DAG Ventures. | verified medium | SRC-001 |
| EC-002 | Nimble operates an active platform for pharmacies, patients and manufacturers, with digital ordering, payments, refills, delivery/pickup and manufacturer adherence/awareness programs. | verified high | SRC-002SRC-003SRC-004SRC-005 |
| EC-003 | IncFact estimates Nimble Rx annual revenue at $10M-$100M and employees at 10-100, while noting private-company revenue estimates are statistical evaluations. | partially verified low | SRC-007 |
| EC-004 | Nimble states that hundreds of independent retail pharmacies rely on the platform to increase revenue, improve operations, ensure compliance and provide patient care. | partially verified medium | SRC-003 |
| EC-005 | Forge lists Nimble as founded in 2015, headquartered in Redwood City, and led by Talha Sattar as CEO and Ryan Brown as CFO. | partially verified medium | SRC-006 |
| EC-006 | The manufacturer page says Nimble enables millions of patients of independent, chain and specialty pharmacies to manage, order and pay for prescriptions online. | partially verified medium | SRC-004 |
| EC-007 | Audited financial statements, take rate, gross margin, customer concentration, churn, manufacturer contract terms and cap table are not public. | not publicly verifiable high | SRC-001SRC-007 |
| EC-008 | Nimble claims integrations with major pharmacy systems, encrypted payment and processing, industry compliance, AWS Secure and LegitScript certification/approval signals. | partially verified medium | SRC-002SRC-003 |
| EC-009 | Competition includes national pharmacy chains, Amazon Pharmacy and prescription-commerce platforms competing for patient convenience, pharmacy workflow and manufacturer access. | partially verified medium | SRC-003SRC-006SRC-007 |
| EC-010 | IncFact lists major pharmacy competitors including CVS Health, CVS Pharmacy, Walgreens and Rite Aid, indicating large incumbent pressure. | partially verified medium | SRC-007 |
| EC-011 | GTM is publicly visible through demo calls, patient app links, pharmacy association/channel signals and manufacturer life-sciences programs. | verified medium | SRC-002SRC-003SRC-004SRC-005 |
| EC-012 | Headcount, compensation, org structure and personnel turnover are only weakly evidenced publicly; exact function/location schedule is private. | not publicly verifiable medium | SRC-006SRC-007 |
| EC-013 | Material legal/regulatory diligence should focus on HIPAA/privacy, pharmacy licensing, payments/PCI, manufacturer marketing compliance, TCPA messaging and vendor security. | partially verified medium | SRC-002SRC-003SRC-004 |
| EC-014 | No public evidence collected showed an IPO, acquisition or shutdown of Nimble Rx; active company pages and private-market profiles support operating status. | partially verified medium | SRC-001SRC-002SRC-006 |
| ID | Publisher | Title | Accessed |
|---|---|---|---|
| SRC-001 | CB Insights | CB Insights The Complete List Of Unicorn Companies | 2026-05-23 |
| SRC-002 | Nimble Rx | Nimble Rx company homepage | 2026-05-23 |
| SRC-003 | Nimble Rx | Nimble for Pharmacies page | 2026-05-23 |
| SRC-004 | Nimble Rx | Nimble for Manufacturers page | 2026-05-23 |
| SRC-005 | Nimble Rx | Nimble for Patients page | 2026-05-23 |
| SRC-006 | Forge Global | Invest and Sell Nimble Rx Stock | 2026-05-23 |
| SRC-007 | IncFact | Annual Report on Nimble Rx Revenue, Growth, SWOT Analysis and Competitor Intelligence | 2026-05-23 |
This report is a public-evidence diligence snapshot, not investment advice. Important financial, legal, technical, and contractual facts remain non-public and should be verified directly with management and primary documents before any investment decision.